The Billion-Dollar Bet That AI Can Skip the Hardest Part of Drug Design

The workflow is iterative, almost like a conversation between the AI and the lab. X-Design proposes antibody sequences. Scientists test them for expression and function. Those results feed back into the model, which learns and refines its next round of designs. Xaira describes this as a "lab-in-the-loop" system, where computational predictions and wet-lab reality constantly sharpen each other.

The underlying technology traces back to David Baker's lab and tools like RFdiffusion and RFantibody, which are generative models capable of designing proteins from scratch. Baker, who is involved with Xaira, said that AI is now beginning to design antibodies entirely de novo (from nothing), which he described as a fundamental shift in what's possible in drug discovery.

The Man Running the Show

Xaira isn't led by a Silicon Valley AI bro. Its CEO, Marc Tessier-Lavigne, is a neuroscientist who previously served as Chief Scientific Officer of Genentech, one of the most successful biotech companies in history. He also served as president of both Rockefeller University and Stanford University. When he calls X-Design "central" to Xaira's strategy, that carries weight in both scientific and business circles.

Tessier-Lavigne co-founded Xaira in 2024 alongside Baker and several other scientists. The company launched with more than $1 billion in committed capital, backed by a murderer's row of investors: ARCH Venture Partners and Foresite Capital led the round, with Sequoia Capital, NEA, Lux Capital, Lightspeed Venture Partners, and others piling in. That's an extraordinary war chest for a company that, at the time, had zero clinical programs.

A Crowded, Fast-Moving Race

Xaira isn't the only company chasing AI-designed antibodies, and the competitive landscape has exploded over the past two years.

Absci is arguably the furthest ahead clinically. By 2025, it had pushed an AI-designed antibody called ABS-101 into a randomized Phase 1 trial, making it the first AI-designed biologic from Absci to enter the clinic. Generate Biomedicines, backed by Flagship Pioneering, is another heavyweight with a broad protein-design platform. Chai Discovery raised significant capital and focuses on generating novel antibody sequences computationally.

Beyond these, a growing roster of specialists is carving out niches: LabGenius in multivalent antibodies, Nabla Bio in generative biologics, Antiverse and EVQLV in computational antibody design. Even traditional antibody discovery companies like AbCellera are layering AI onto their existing platforms.

The question isn't whether AI will play a role in antibody discovery. It already does. The question is whether any of these platforms can reliably produce molecules that survive the brutal gauntlet from lab to clinic to pharmacy shelf.

The "So What" for the Industry

Xaira also teased a second internal program targeting a GPCR (a type of cell surface receptor) that the company described as otherwise "intractable," meaning traditional methods couldn't crack it. No target names or timelines were disclosed, which keeps the hype tempered by a healthy dose of mystery.

The broader signal is clear, though. Xaira is positioning itself not as an AI tool vendor that licenses technology to pharma companies, but as a fully integrated drug maker that discovers, designs, and develops its own therapeutics. That's a much bigger, much riskier bet. It's also the bet that could produce the biggest payoff.

Biotech has seen plenty of platform stories that promised the world and delivered PowerPoint slides. What makes Xaira interesting is the combination: Baker's protein-design technology, Tessier-Lavigne's drug development pedigree, a billion dollars in the bank, and early proof-of-concept data like that seven-week cancer candidate.

None of that guarantees success. Biology is stubbornly good at humbling even the best-funded efforts. But if X-Design can consistently produce antibodies that skip years of optimization, it won't just be a better mousetrap. It'll be a different game entirely.

Bayer Just Bet $2.2 Billion That Ohio Is the Future of Pharma

Bayer is pouring $2.2 billion into its first-ever North American pharma manufacturing campus in Ohio. The move signals the German giant's biggest bet yet on U.S.-made drugs, but the factory won't produce a single pill until 2031.